A detailed history of Financial Advisors Network, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Financial Advisors Network, Inc. holds 4,554 shares of BMY stock, worth $253,976. This represents 0.05% of its overall portfolio holdings.

Number of Shares
4,554
Previous 4,300 5.91%
Holding current value
$253,976
Previous $249,000 6.43%
% of portfolio
0.05%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $12,313 - $14,693
254 Added 5.91%
4,554 $233,000
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $248,927 - $278,339
4,300 New
4,300 $249,000
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $719,623 - $862,892
-11,705 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $38,238 - $44,576
-713 Reduced 5.74%
11,705 $730,000
Q3 2021

Dec 27, 2021

BUY
$59.17 - $69.31 $67,867 - $79,498
1,147 Added 10.18%
12,418 $738,000
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $16,529 - $18,001
267 Added 2.43%
11,271 $753,000
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $373,129 - $419,661
6,288 Added 133.33%
11,004 $695,000
Q4 2020

Feb 11, 2021

SELL
$57.74 - $65.43 $7,332 - $8,309
-127 Reduced 2.62%
4,716 $293,000
Q3 2020

Nov 13, 2020

SELL
$57.43 - $63.64 $37,903 - $42,002
-660 Reduced 11.99%
4,843 $292,000
Q2 2020

Aug 11, 2020

SELL
$54.82 - $64.09 $63,591 - $74,344
-1,160 Reduced 17.41%
5,503 $324,000
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $309,163 - $449,286
6,663 New
6,663 $371,000
Q1 2019

Jun 04, 2019

SELL
$45.12 - $53.8 $194,963 - $232,469
-4,321 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $210,691 - $273,216
4,321 New
4,321 $225,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $119B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Financial Advisors Network, Inc. Portfolio

Follow Financial Advisors Network, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Advisors Network, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Advisors Network, Inc. with notifications on news.